PMID- 9862726
OWN - NLM
STAT- MEDLINE
DCOM- 19990122
LR  - 20220318
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 161
IP  - 12
DP  - 1998 Dec 15
TI  - The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, 
      and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells.
PG  - 6924-30
AB  - We and others have demonstrated previously the occurrence of cC1qR/CaR, a 
      receptor for the collagen-like stalks of complement component C1q, on endothelial 
      cells. In the present study we investigated whether binding of C1q to endothelial 
      cells resulted in enhancement of cytokine or chemokine production. HUVEC produced 
      82 +/- 91 pg/ml of IL-8, 79 +/- 113 pg/ml of IL-6, and 503 +/- 221 pg/ml of 
      monocyte chemoattractant peptide-1 (MCP-1) under basal conditions. Incubation 
      with C1q resulted in a time- and dose-dependent up-regulation of IL-8 (1012 +/- 
      43 pg/ml), IL-6 (392 +/- 20 pg/ml), and MCP-1 (2450 +/- 101 pg/ml). This 
      production is dependent on de novo protein synthesis, as demonstrated by the 
      detection of specific mRNA after C1q stimulation, and inhibition of peptide 
      production in the presence of cycloheximide. The production of all factors was 
      inhibited (69 +/- 7%) by the collagenous fragments of C1q, while the C1q globular 
      heads only induced 13 +/- 11% inhibition. When HUVEC were incubated with C1q in 
      the presence of aggregated IgM, enhanced production of IL-8 (2500 +/- 422 pg/ml), 
      IL-6 (997 +/- 21 pg/ml), and MCP-1 (5343 +/- 302 pg/ml) was found. Furthermore, 
      F(ab')2 anti-calreticulin partially inhibited the production of IL-8, confirming 
      at least the involvement of cC1qR/CaR. These experiments suggest that in an 
      inflammatory response C1q not only is able to activate the complement pathway, 
      but when presented in a proper fashion also might induce the production of 
      factors that contribute to acute phase responses and recruitment of inflammatory 
      cells.
FAU - van den Berg, R H
AU  - van den Berg RH
AD  - Department of Nephrology, Leiden University Hospital, The Netherlands.
FAU - Faber-Krol, M C
AU  - Faber-Krol MC
FAU - Sim, R B
AU  - Sim RB
FAU - Daha, M R
AU  - Daha MR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CFH protein, human)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Calreticulin)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Synthesis Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ribonucleoproteins)
RN  - 80295-33-6 (Complement C1q)
RN  - 80295-65-4 (Complement Factor H)
RN  - 98600C0908 (Cycloheximide)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Calcium-Binding Proteins/antagonists & inhibitors/immunology/physiology
MH  - Calreticulin
MH  - Cells, Cultured
MH  - Chemokine CCL2/*biosynthesis/genetics
MH  - Complement C1q/*pharmacology
MH  - Complement Factor H/analysis
MH  - Cycloheximide/pharmacology
MH  - Dose-Response Relationship, Immunologic
MH  - Endothelium, Vascular/*drug effects/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunoglobulin Fab Fragments/pharmacology
MH  - Immunoglobulin M/pharmacology
MH  - Interleukin-6/*biosynthesis/genetics
MH  - Interleukin-8/*biosynthesis/genetics
MH  - Peptide Fragments/pharmacology
MH  - Protein Synthesis Inhibitors/pharmacology
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Rabbits
MH  - Ribonucleoproteins/antagonists & inhibitors/immunology/physiology
MH  - Stimulation, Chemical
MH  - Umbilical Veins
EDAT- 1998/12/23 00:00
MHDA- 1998/12/23 00:01
CRDT- 1998/12/23 00:00
PHST- 1998/12/23 00:00 [pubmed]
PHST- 1998/12/23 00:01 [medline]
PHST- 1998/12/23 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1998 Dec 15;161(12):6924-30.